SCHEMBL6368466

SCHEMBL6368466

CCOC(=O)Cc1cccc(NCC(=O)OC(C)(C)C)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FPR3 P25089 1/20 0.44
FPR2 P25090 1/20 0.44
POLB P06746 1/20 0.42
MAPT P10636 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
LMNA P02545 1/20 0.42
PPID Q08752 1/20 0.41
HTT P42858 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
IDH1 O75874 1/20 0.40
ALDH1A1 P00352 1/20 0.40
SYK P43405 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
EGFR P00533 1/20 0.39
CCNT1 O60563 1/20 0.39
BRD4 O60885 1/20 0.38
GRK2 P25098 1/20 0.38
NR1H4 Q96RI1 1/20 0.38
NPC1 O15118 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15876051 0.91 FPR3 (0.48) FPR3FPR2MAPTSMN1; SMN2LMNA
SCHEMBL20798155 0.85 FPR3 (0.48) FPR3FPR2MAPTSMN1; SMN2LMNA
SCHEMBL6371460 0.84 LMNA (0.48) MAPTSMN1; SMN2LMNAHTTALDH1A1
SCHEMBL24077532 0.81 ALDH1A1 (0.53) POLBMAPTSMN1; SMN2LMNAALDH1A1
SCHEMBL12121617 0.80 MAPT (0.55) POLBMAPTLMNAHTTALDH1A1
SCHEMBL18311592 0.79 MAPK1 (0.51) POLBMAPTSMN1; SMN2LMNAHTT
SCHEMBL2636349 0.78 HTT (0.45) MAPTSMN1; SMN2LMNAPPIDHTT
SCHEMBL5089369 0.78 MAPT (0.43) MAPTSMN1; SMN2LMNAHTTL3MBTL1
SCHEMBL11355645 0.78 POLB (0.55) POLBMAPTSMN1; SMN2LMNAPPID
SCHEMBL28250673 0.78 POLB (0.47) POLBPPIDIDH1SYKBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6838478-B2 Amino acid derivatives and their use as thrombin inhibitors ASTRAZENECA AB (SE) 2005-01-04 US disclosed
EP-0910573-B1 NEW AMINO ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS ASTRAZENECA AB (SE) 2003-01-29 EP disclosed
US-20020019371-A1 New amino acid derivatives and their use as thrombin inhibitors ASTRAZENECA AB 2002-02-14 US disclosed
US-6255301-B1 CARDIOVASCULAR DISORDERS; ANTICOAGULANT; PROTEASE INHIBITORS ASTRAZENECA AB (SE) 2001-07-03 US disclosed
EP-0910573-A1 NEW AMINO ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS Astra Aktiebolag (SE) 1999-04-28 EP disclosed
WO-1997046577-A1 NEW AMINO ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS ASTRA AKTIEBOLAG (SE) 1997-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019371-A1 New amino acid derivatives and their use as thrombin inhibitors F2, SERPINC1, FGB FPR3 167/4885FPR2 272/4885POLB 2344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.